NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 13 December 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Dr Peter Baker-Gulliver Present for all items
5. Richard Ballerand Present for all items
6. Dr Craig Buckley Present for all items
7. Dr Andrew Champion Present for all items
8. Dr Louis Choo Present for all items
9. Dr Justin Daniels Present for all items
10. Ana Duarte Present for all items
11. Dr Steve Edwards Items 1 to 4.3.2
12. Mohamad Farhat Present for all items
13. Professor Khalida Ismail Present for all items
14. Dr Fiona MacPherson Smith Present for all items
15. Professor G.J. Melendez-Torres Items 5.2 to 5.2.2
16. Dr Pratheeban Nambyiah Present for all items
17. Hugo Pedder Present for all items
18. Becky Pennington Present for all items
19. Dominic Pivonka Items 5 to 5.2.2
20. Dr Mohit Sharma Present for all items
21. Alan Thomas Present for all items
22. Min Ven Teo Present for all items

NICE staff (key players) present

Henry Edwards, Associate Director Items 1 to 4.3.2

Janet Robertson, Associate Director Items 5 to 5.2.2

Dan Davis, Project Manager Items 1 to 4.3.2

Thomas Feist, Project Manager Items 5 to 5.2.2

Mary Hughes, Heath Technology Assessment Adviser Items 1 to 4.3.2

Joanna Richardson, Heath Technology Assessment Adviser Items 5 to 5.2.2

Marcela Haasova, Heath Technology Assessment Analyst Items 1 to 4.3.2

Alexandra Sampson, Heath Technology Assessment Analyst Items 5 to 5.2.2

Adam Storrow, Business Analyst, RIA Present for all items

Ruth Melville, Senior Medical Editor Items 1 to 4.3.2

Olivia Waring, Senior Medical Editor Items 5 to 5.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.3.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 5 to 5.1.3

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Rumana Zaman, Administrator, TA Items 1 to 4.3.2

Marcia Miller, Administrator, TA Items 5 to 5.1.3

NICE staff (observers) present

Leonardo Koeser, Scientific Adviser – NICE Scientific Advice Items 1 to 4.3.2

Carl Prescott, Senior Technical Adviser - Methods Implementation Items 1 to 4.3.2

Emily Eaton Turner, Technical Adviser, Commercial Liaison team Items 5 to 5.2.2

Sarah Wilkes, Technical Analyst, Commercial Liaison team role Items 5 to 5.2.2

Thomas Palmer, Technical Analyst, Interventional Procedures team Items 5 to 5.2.2

Milena Wobbe, Technical Analyst, Managed Access team Items 5 to 5.2.2

Denise Moyo, Coordinator, Committee Operations Team Present for all items

External assessment group representatives present

G.J. Melendez-Torres, Peninsula Technology Assessment Group, University of Exeter (PenTAG), Items 1 to 4.2.1

Jaesh Naik, Peninsula Technology Assessment Group, University of Exeter (PenTAG), Items 1 to 4.2.1

Vicky Wakefield, BMJ Group, Items 5 to 5.1.3

Tracey Jhita, BMJ Group, items 5 to 5.1.3

Clinical & Patient experts present

Amy Deptford, Patient expert nominated by Crohn’s & Colitis UK, Items 1 to 4.1.3

Kamila Kingstone, Patient expert nominated by Crohn’s & Colitis UK, Items 1 to 4.1.3

Dr Mark Samaan, Consultant Gastroenterologist, clinical expert nominated by AbbVie Ltd, Items 1 to 4.1.3

Dr Mohammed Nabil Quraishi, Consultant Gastroenterologist and IBD specialist, clinical expert nominated by The British Society of Gastroenterology, Items 1 to 4.1.3

Professor Jonathan A Ledermann, Professor of medical Oncology and Consultant Medical Oncologist, clinical expert nominated by AstraZeneca, Items 5 to 5.1.3

Dr Rebecca Bowen, Medical Oncologist, clinical expert nominated by the British Gynaecological Cancer Society (BGCS), Items 5 to 5.1.3

Rachel Downing, Patient expert nominated by Target Ovarian Cancer, Items 5 to 5.1.3

Florence Wilks, Patient expert nominated by Ovarian Cancer Action , Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr James Fotheringham welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr David Maudgil, Min Ven Teo, Dr Mohit Sharma and Dr Peter Baker-Gulliver.

### News and announcements

* 1. Committee welcomed new member Mohamad Farhat to his role as Clinical Pharmacist.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 8 November 2022.

### Appraisal of risankizumab for previously treated moderately to severely active Crohn's disease [ID3986]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AbbVie.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Abdallah Al-Mohammad declared financial interests as he has received honoraria for lectures from AstraZeneca, Janssen, Takeda and Pharmacosmos, honoraria for attending advisory boards with Novartis, Pharmacosmos and AstraZeneca and he is due to carry out research with Pfizer and possibly with both AstraZeneca and Novartis in 2023. Professor Al-Mohammad confirmed all the above were in cardiology and mainly in heart failure. None of them were related to this appraisal. It was agreed that his declaration would not prevent Professor Al-Mohammad from participating in discussions on this appraisal.
* Committee member Becky Pennington declared financial interests as she has received payment from Takeda for private consultancy work. Becky confirmed the work was related to methodological research on the inclusion of carers in economic evaluation and that the work was not specific to any drug and not related to Crohn's. It was agreed that his declaration would not prevent Becky from participating in discussions on this appraisal.
* Committee member Dominic Pivonka declared financial interests as his employer (AbbVie) is the company sponsor and a possible comparator company as a direct conflict Dominic did not participate in discussions for this appraisal.
* Nominated clinical expert Dr Mark Samaan declared direct financial interests as he has received advisory board fees from Janssen, Takeda, Sandoz, Samsung, Bioepis, Galapagos and AbbVie, and lecture fees from Bristol-Myers Squibb, Janssen, Takeda, MSD, Falk, AbbVie, and Galapagos. It was agreed that his declaration would not prevent Dr Samaan from providing expert advice to the committee
* No further interests were declared for this appraisal.
  + 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Abdallah Al-Mohammad, Richard Ballerand, and Hugo Pedder.
  1. Part 2a – Closed session (company representatives, all experts, and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10884>

### Appraisal of olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (managed access review of TA620) [ID3788]

* 1. Part 1 – Open session
     1. The chair Dr Radha Todd welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Abdallah Al-Mohammad declared financial interests as he has received honoraria for lectures from AstraZeneca, Janssen, Takeda and Pharmacosmos, honoraria for attending advisory boards with Novartis, Pharmacosmos and AstraZeneca and he is due to carry out research with Pfizer and possibly with both AstraZeneca and Novartis in 2023. Professor Al-Mohammad confirmed all the above were in cardiology and mainly in heart failure. None of them were related to this appraisal. It was agreed that his declaration would not prevent Professor Al-Mohammad from participating in discussions on this appraisal.
* Committee member Dr Steve Edwards is a member of the EAG for this appraisal, as a direct conflict Steve did not participate in discussion on this appraisal.
* Nominated clinical expert Professor Jonathan A Ledermann declared

direct financial and personal interestas he has attended advisory boards and received lecture fees from GSK; AstraZeneca; Clovis Oncology; Eisai; MSD/Merck; Artios Pharma; Regeneron; VBL Therapeutics; Bristol Myers Squibb; Nuvation andhas received research grants paid to the University from AstraZeneca; MSD/Merck. He is also clinical investigator on trials with niraparib, olaparib and rucaparib in recurrent ovarian cancer, Editor Gynaecological Cancer Track, ESMO Clinical Practice Guidelines and Past Vice President, ESGO. It was agreed that his declaration would not prevent Professor Ledermann from providing expert advice to the committee.

* Nominated clinical expert Dr Rebecca Bowen declared direct financial interests as she has received honoraria for presentations on BRCA/HRD testing and advisory boards from AstraZeneca. It was agreed that her declaration would not prevent Dr Bowen from providing expert advice to the committee.
* Nominated patient expert Florence Wilks declared Indirect interests as in the last 12 months Ovarian Cancer Action received funding from GSK to support national clinical service improvement policy work. It was agreed that her declaration would not prevent Florence from providing expert advice to the committee.
* Nominated patient expert Rachel Downing declared Indirect interests as in the last 12 months Target Ovarian Cancer received funding from GSK for Target Ovarian Cancer’s support line. It was agreed that her declaration would not prevent Rachel from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Andrew Champion, Becky Pennington, and Richard Ballerand.
  1. Part 2 – Closed session (company representatives, clinical & patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10712>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 10 January 2023 and will start promptly at 09.30.